Quest Partners LLC Buys Shares of 1,178 IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Quest Partners LLC purchased a new stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 1,178 shares of the company’s stock, valued at approximately $41,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in IDEAYA Biosciences by 19.6% in the 1st quarter. Vanguard Group Inc. now owns 4,155,757 shares of the company’s stock valued at $182,355,000 after buying an additional 679,985 shares during the last quarter. Capital Research Global Investors lifted its holdings in shares of IDEAYA Biosciences by 43.6% during the fourth quarter. Capital Research Global Investors now owns 1,976,870 shares of the company’s stock worth $70,337,000 after purchasing an additional 600,000 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in IDEAYA Biosciences by 17.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,566,278 shares of the company’s stock valued at $126,889,000 after purchasing an additional 535,909 shares during the period. Fisher Asset Management LLC increased its holdings in IDEAYA Biosciences by 1,611.9% in the fourth quarter. Fisher Asset Management LLC now owns 539,676 shares of the company’s stock valued at $19,202,000 after purchasing an additional 508,151 shares during the period. Finally, First Light Asset Management LLC bought a new position in IDEAYA Biosciences during the 4th quarter worth $12,299,000. 98.29% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

IDYA has been the topic of a number of analyst reports. Stifel Nicolaus upped their price target on IDEAYA Biosciences from $63.00 to $68.00 and gave the company a “buy” rating in a research report on Tuesday, September 10th. Mizuho initiated coverage on shares of IDEAYA Biosciences in a research report on Monday, July 8th. They set an “outperform” rating and a $50.00 target price for the company. Citigroup dropped their price target on shares of IDEAYA Biosciences from $60.00 to $58.00 and set a “buy” rating on the stock in a research report on Tuesday, August 27th. Oppenheimer decreased their price objective on shares of IDEAYA Biosciences from $60.00 to $53.00 and set an “outperform” rating for the company in a research report on Wednesday, August 7th. Finally, JPMorgan Chase & Co. dropped their target price on shares of IDEAYA Biosciences from $69.00 to $66.00 and set an “overweight” rating on the stock in a report on Thursday, August 8th. Twelve equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $56.20.

IDEAYA Biosciences Price Performance

Shares of IDEAYA Biosciences stock opened at $34.75 on Thursday. The firm has a market cap of $2.63 billion, a PE ratio of -17.29 and a beta of 0.84. IDEAYA Biosciences, Inc. has a 1 year low of $23.41 and a 1 year high of $47.74. The stock has a fifty day moving average price of $39.10 and a 200-day moving average price of $39.86.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.14). IDEAYA Biosciences had a negative return on equity of 20.52% and a negative net margin of 483.05%. During the same quarter in the prior year, the business posted ($0.50) earnings per share. As a group, equities analysts anticipate that IDEAYA Biosciences, Inc. will post -2.51 EPS for the current fiscal year.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.